Skip to main content
Clinical Trials/NCT06104852
NCT06104852RecruitingNot Applicable

Triage Survey for Neurology Research Eligibility

Adams Clinical3 sites in 1 country600 target enrollmentStarted: June 2, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
600
Locations
3
Primary Endpoint
Proportion of the clinical trial seeking population for whom industry-sponsored clinical research is clinically appropriate, as defined as those who go on to screen for a study.

Study Overview

Brief Summary

TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.

Detailed Description

TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials. Secondary objectives include identifying participant characteristics among the clinical trial-seeking population, identifying the percentage of potential participants currently taking prescribed memory medications that could exclude them from clinical trial participation, examining how changes in prescription memory medications impact performance on cognitive assessments, and identifying the percentage of potential participants whose laboratory results could exclude them from clinical trial participation.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Participant and study partner (when applicable) have signed an ICF prior to study-specific procedures being performed.
  • Participant and study partner (when applicable) are at least 18 years old.

Exclusion Criteria

  • Participant lacks the language skills or cognitive ability to understand the screening process.
  • Participant is pregnant, breast-feeding, or planning to become pregnant.
  • History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results.
  • Participant represents an acute suicidal risk, as defined as a "yes" response to ideation on Columbia-Suicide Severity Rating Scale questions 4 or 5, or answer "yes" to behavior questions within 90 days of screening.
  • Moderate or severe substance use disorder within 90 days prior to screening, according to DSM-5 criteria that in the investigator's opinion could pose undue risk to the participant.
  • Any condition that in the investigator's opinion makes a participant unsuitable for the study.
  • Currently employed by Adams Clinical or a first-degree relative of an employee working on this study.

Outcomes

Primary Outcomes

Proportion of the clinical trial seeking population for whom industry-sponsored clinical research is clinically appropriate, as defined as those who go on to screen for a study.

Time Frame: Up to 52 weeks

Secondary Outcomes

  • Proportion of the clinical trial seeking population who enroll in industry-sponsored studies.(Up to 52 weeks)
  • Change in performance on the Mini Mental Status exam for individuals who discontinue memory medications.(Up to 52 weeks)
  • Changes in score on the Neuropsychiatric Inventory Questionnaire for individuals who discontinue memory medications.(Up to 52 weeks)

Investigators

Sponsor
Adams Clinical
Sponsor Class
Network
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials

Triage Survey for Neurology Research... | Clinical Trial